USPTO serial 79354991
REPHINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 30, 2024
- Examiner
- LOZEAU, BRANDON THOMAS
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with REPHINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Pharmaceutical product evaluation; quality audits in the nature of product quality evaluation; product quality control testing; product safety testing services; testing services in the field of manufacturing safety; quality assurance consultancy in the field of pharmaceuticals and the manufacture of pharmaceuticals; inspection services of pharmaceuticals and manufacturing processes for pharmaceuticals for quality control; inspection of manufacturing processes to determine conformance with certification standards for quality, reliability, and safety; inspection of pharmaceuticals; product quality testing services; testing of pharmaceuticals; quality control for others to determine conformance with established product certification standards; product quality evaluation services in the nature of quality control for others; industrial analysis services in the field of pharmaceuticals and manufacturing processes for pharmaceuticals; testing, inspection, quality control, evaluation, verification and analysis of medical products and pharmaceuticals for others; testing, inspection, quality control, verification, evaluation and analysis of medical products and pharmaceuticals for others for compliance with quality standards; testing, quality control inspection, evaluation, verification and analysis of quality management systems, manufacturing systems, manufacturing methods and manufacturing processes; conducting clinical trials for others; scientific research in the nature of scientific study protocol development; research and development in the pharmaceutical field; information, advisory and consultancy services in relation to the aforesaid | ACTIVE | — |
| 045 | Regulatory compliance auditing; legal compliance auditing; good manufacturing practices audit in the nature of legal compliance auditing; advisory services relating to regulatory affairs in the field of the manufacture of pharmaceuticals; reviewing standards and practices to assure compliance with manufacturing process safety, product safety and product packaging laws and regulations; legal and regulatory information services relating to pharmaceutical manufacturing standards; analysis of data, policy and process, and provision of advice and assistance relating to standards and practices to ensure compliance with manufacturing process safety, product safety and product packaging laws and regulations; legal and regulatory compliance consulting services in the field of the manufacture of pharmaceuticals; legal and regulatory advisory and consultancy services in relation to clinical trials; provision of information and advice relating to regulatory compliance systems in the field of the manufacture of pharmaceuticals; legal services, namely, legal risk assessment services for the security of goods and individuals; project management consulting services relating to regulatory compliance requirements for pharmaceutical manufacturing safety and security; regulatory compliance consulting in the field of the manufacture of pharmaceuticals, namely, provision of benchmarking and reference information relating to pharmaceutical safety standards; information, advisory and consultancy services in relation to the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 14, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 17, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 26, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 26, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 30, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 30, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 30, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 29, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 10, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 10, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 14, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 13, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 13, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 24, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 24, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 10, 2024 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 10, 2024 | ALIE | ASSIGNED TO LIE | — |
| Nov 22, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 22, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 22, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 22, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 22, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 14, 2023 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 3, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Sep 18, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 14, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 14, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 14, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 14, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 17, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 17, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 17, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 17, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 21, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 20, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 20, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 18, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 1, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 1, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 4, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 3, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 18, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 14, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 10, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |